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SUMMARY
Seroconversion illness is known to be associated with more rapid HIV disease progression.
However, symptoms are often subjective and prone to recall bias. We describe symptoms
reported as seroconversion illness and examine the relationship between illness, HIV test interval
(time between antibody-negative and anibody-positive test dates) and the eﬀect of both on time to
AIDS from seroconversion. We used a Cox model, adjusting for age, sex, exposure group and
year of estimated seroconversion. Of 1820 individuals, information on seroconversion illness was
available for 1244 of whom 423 (34%) reported symptomatic seroconversion. Persons with a
short test interval (f2 months) were signiﬁcantly more likely to report an illness than people with
a longer interval (OR 6.76, 95% CI 4.75–9.62). Time to AIDS was signiﬁcantly faster (P=0.01)
in those with a short test interval. The HIV test interval is a useful replacement for information
on seroconversion illness in studies of HIV disease progression.
INTRODUCTION
The presence of seroconversion illness, typically
characterized by ‘ ’ﬂu-like’ symptoms, including
fever, malaise, night sweats, generalized lymphade-
nopathy, skin rashes and diarrhoea, in the course of
HIV infection has been well documented [1–3]. Pre-
vious studies have reported an association between
illness at the time of seroconversion and a more rapid
disease progression [2, 4, 5]. However, the proportion
of individuals who experience illness during primary
infection is uncertain, because symptoms are neither
sensitive nor speciﬁc enough to HIV infection, and are
subject to recall bias at the time of the HIV-positive
test. Lack of such information from clinical notes may
mean either that the infected individual did not
experience a seroconversion illness, or simply that
such information was not sought and is, therefore,
unknown.
Presence of symptoms may prompt some individ-
uals, who believe they may recently have been
exposed to HIV, to seek medical advice. If the clin-
ician suspects seroconversion illness, an antibody test
may be requested. If the individual is seroconverting
to HIV at this time, the ﬁrst test may be negative and
clinicians are likely to follow up with a repeat test,
which will be positive, a few weeks later. Alterna-
tively, an individual who has regular HIV tests, may
test positive for HIV when presenting to the clinician
with a seroconversion illness. In both cases, the HIV
test interval (time between last negative and ﬁrst
positive test dates) is likely to be shorter than that of
patients without a seroconversion illness. Thus, the
length of the HIV test interval may serve as a simple
means of adjusting for seroconversion illness where
illness is poorly recorded or information is not
available. A recent study proposed using the HIV
test interval as a proxy for seroconversion illness
and reported that a short HIV test interval of
f31 days was associated with a more rapid disease
* Author for correspondence: Dr K. Porter, MRC Clinical Trials
Unit, 222 Euston Road, London NW1 2DA, UK.
Epidemiol. Infect. (2003), 131, 1117–1123. f 2003 Cambridge University Press
DOI: 10.1017/S0950268803001377 Printed in the United Kingdomprogression [6]. However, information on sero-
conversion illness was not available in that study.
Here we describe reported symptoms compatible
with HIV seroconversion and trends over time. We
also investigate the relationship between reported
seroconversion illness and HIV test interval and in-
vestigate the inﬂuence of both on the time between
HIV seroconversion and AIDS.
METHODS
We used data from individuals enrolled on the UK
Register of HIV Seroconverters reported by January
2002. The Register has been described in detail else-
where [7, 8], but brieﬂy, is a cohort of HIV-infected
individuals aged 16 years or over with a history of a
documented negative test within 3 years of a ﬁrst
positive test, or identiﬁed during the acute infection
stage (based on strictly deﬁned laboratory evidence of
seroconversion). The date of seroconversion is taken
as the date of laboratory evidence where known,
otherwise it is the midpoint between the positive and
negative test dates. Eligible subjects were enrolled
from October 1994 and were identiﬁed both retro-
spectively and prospectively. Complete ascertainment
of all eligible seroconverters was sought, including
those who had died, transferred to other centres or
become lost to follow up. All symptoms, described in
the literature as suggestive of HIV seroconversion
illness, were recorded in a standardized format [1–3].
We examined the relationship between the presence
of illness and HIV test interval initially by examining
the proportions of individuals reporting illness who
have short and long test intervals and by then esti-
mating the relative odds of reporting an illness in
persons with a short test interval. We initially deﬁned
a test interval as short if it was less than 1 month and
redeﬁned it with increasingly longer lengths to explore
any ‘dose–response’ relationship between the length
of the test interval and HIV seroconversion illness.
We then used logistic regression models to investi-
gate the association between the presence of sero-
conversion illness as the outcome variable and the
HIV test interval, adjusting for sex, exposure cat-
egory, age at seroconversion (16–19, 20–29, 30–39,
40+ years) and estimated year of seroconversion
(1982–1989, 1990–1993, 1994–1997, 1998–2000).
Using log-rank methods and Cox proportional
hazards models [9] we investigated the association
between the presence of seroconversion illness, the
HIV test interval and the time interval between HIV
seroconversion and AIDS, also adjusting for the
possible eﬀects of sex, age at seroconversion (grouped
as above), exposure category and calendar year at risk
(as a time-dependent covariate) allowing for late entry
[10]. AIDS was deﬁned using the European case deﬁ-
nition [11] and follow up was censored on the 31
December 2000. Persons not reported as AIDS to
CDSC and SCIEH (the national AIDS reporting
centres) by 31 December 2001 were assumed to be
AIDS-free on 31 December 2000, thus allowing for a
1 year reporting delay. Persons who had moved
abroad (n=24) or who had not been seen after
January 1990 (n=13) were censored on the date they
were last assessed in the clinic. Persons who died
without AIDS (n=116) were censored on the date of
death.
We repeated the analyses, restricting this to persons
reported prospectively from 1994. We also carried out
a sensitivity analysis, restricted to persons with a HIV
test interval f12 months, and measured time from
the ﬁrst positive date, rather than the midpoint.
RESULTS
Of 1820 seroconverters, 476 (26%) were diagnosed
with AIDS and 424 (23%) died. The majority of sero-
converters were men infected through sex between
men (81%). Median year of estimated seroconversion
was 1992 (range 1982–2000). Of 1244 individuals with
information available on the presence (or absence) of
illness at seroconversion, 423 (34%) reported symp-
toms suggestive of seroconversion illness.
As expected, completeness of reporting absence or
presence of a seroconversion illness improved over
time with information on illness known for 59% (643/
1081) of seroconverters reported retrospectively,
compared to 81% (601/739) of seroconverters re-
ported prospectively (Table 1). General, non-speciﬁc
symptoms accounted for approximately 90% of all
events reported and varied little over time. Of interest,
8 (2%) individuals experienced more severe symp-
toms including AIDS-deﬁning events.
Individuals with a short test interval were more
likely to report a seroconversion illness than persons
with a long test interval. We found that the shorter
our deﬁnition of the test interval, the more likely was
a seroconversion illness to have been reported com-
pared to a long test interval (Fig. 1), the strongest
association occurring at a test interval of f1 month
(OR 7.51, 95% CI 4.95–11.58) but with maximal
discrimination of 2–3 months (OR 6.96, 95% CI
1118 F. Tyrer and othersTable 1. Proportion of persons reporting symptoms compatible with HIV seroconversion illness over time and
trends in reports of the most commonly reported symptoms
Estimated year of seroconversion …
Collected retrospectively Collected prospectively
Total
n (%)
1982–1990
n (%)
1990–1993
n (%)
1994–1997
n (%)
o1998
n (%)
Number of individuals
490 591 460 279 1820
No information on seroconversion illness 237 201 118 20 576
Information on seroconversion illness 253 390 342 259 1244
No seroconversion illness reported 193 (76) 270 (69) 210 (61) 148 (57) 821 (66)
Seroconversion illness reported 60 120 132 111 423
Symptoms*
n (% of 60) n (% of 120) n (% of 132) n (% of 111) n (% of 423)
’Flu-like illness 12 (20) 29 (24) 35 (27) 40 (36) 116 (27)
Rash, erythema 15 (25) 24 (20) 31 (22) 44 (40) 114 (27)
Chills, fever, night sweats 15 (25) 32 (26) 36 (27) 30 (27) 113 (27)
Lymphadenopathy unspeciﬁed 11 (18) 19 (16) 16 (12) 23 (21) 69 (16)
Upper respiratory tract infection 13 (22) 23 (19) 17 (13) 13 (12) 66 (16)
Tiredness, lethargy 9 (15) 12 (10) 21 (16) 17 (15) 59 (14)
Nausea, vomiting, loss of appetite 6 (10) 8 (7) 9 (7) 19 (17) 42 (10)
Gastrointestinal problems 7 (12) 7 (6) 15 (11) 9 (8) 38 (9)
Weight loss, cachexia 6 (10) 8 (7) 6 (5) 3 (3) 23 (5)
Headache 2 (3) 4 (3) 7 (5) 7 (6) 20 (5)
Severe illness# 3 (5) 1 (1) 3 (2) 1 (1) 8 (2)
* Percentages relate to the number of individuals reporting presence of seroconversion illness citing these speciﬁc symptoms.
# Oesophageal candida (n=3), encephalitis (n=2), viral meningitis (n=2), bacterial meningitis (n=1).
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Fig. 1. Proportion of persons reporting an HIV seroconversion illness by varying lengths of HIV test interval (n=1244).
(Test interval is the interval between the last antibody-negative and ﬁrst antibody-positive test dates.)
Seroconversion illness and time to AIDS 11194.90–9.96, and OR 4.95, 95% CI 3.68–6.66 for
lengths f2 and f3 months respectively). Thus we
used a test interval of f2 months to best approximate
the presence of seroconversion illness.
We found that a HIV test interval of f2 months
was strongly independently associated with reporting
a seroconversion illness after adjusting for other
demographic factors (OR 6.76, 95% CI 4.75–9.62)
(Table 2). Further, persons seroconverting in the lat-
ter periods were also more likely to report a sero-
conversion illness (P<0.001). We found evidence
that older individuals were more likely to report an
illness (P=0.04), but no evidence to suggest that sex
or exposure category were associated with reporting a
seroconversion illness (P=0.33 and 0.40 respectively).
Kaplan–Meier estimates showed that progression
to AIDS appeared to be faster in those with a short
HIV test interval compared to those with a long test
interval (log-rank P=0.02). At 10 years following
seroconversion we estimated an AIDS-free survival of
68.0a n d7 3 .6% for those with short and long HIV
test intervals respectively (Fig. 2).
In assessing the eﬀect of covariates on the risk of
AIDS, the HIV test interval was more prognostic than
seroconversion illness. We found no evidence of an
independent association between seroconversion ill-
ness and the risk of AIDS in our cohort (P=0.82)
(Table 3). In contrast, we found that persons with a
short HIV test interval were at a greater risk of AIDS
than persons with a long test interval, both uni-
variately [HR (hazards ratio) 1.37, 95% CI 1.04–
1.81], and after adjustment for age, seroconversion
illness, sex, exposure group and calendar year (HR
1.49, 95% CI 1.11–2.00). Older individuals (P=0.03),
injecting drugs users (P heterogeneity=0.04) and
those at risk in more recent calendar years (P<0.001)
were also signiﬁcantly associated with the progression
to AIDS. Similar results were observed when we re-
stricted the analysis to 739 individuals enrolled pro-
spectively (HR 1.31 for AIDS, adjusted for age, sex,
illness, exposure category and calendar year, 95% CI
0.51–3.35).
When we restricted analyses to persons with a HIV
test interval of f12 months, we found that persons
Table 2. Factors associated with reporting a HIV seroconversion illness* (n=1244)
Variable
Univariate Multivariate*
OR 95% CI P value OR 95% CI P value
HIV test interval
>2 months 1.00 <0.001 1.00 <0.001
f2 months 6.86 4.86–9.68 6.76 4.75–9.62
Sex
Male 1.00 0.44 1.00 0.33
Female 1.22 0.74–1.99 1.46 0.68–3.14
Age group (years)
16–19 0.56 0.24–1.31 0.002 0.53 0.21–1.30 0.04
20–29 1.00 1.00
30–39 1.33 1.02–1.75 1.22 0.91–1.63
40+ 1.77 1.25–2.50 1.51 1.04–2.20
Exposure category
Sex between men 1.00 0.26 1.00 0.40
Injecting drug use 0.55 0.26–1.16 0.67 0.29–1.52
Sex between men
and women
1.23 0.81–1.86 1.39 0.73–2.64
Other/unknown 1.30 0.36–4.63 0.71 0.17–2.89
Year of seroconversion
1982–1989 1.00 <0.001 1.00 <0.001
1990–1993 1.55 1.06–2.27 1.59 1.05–2.39
1994–1997 2.16 1.48–3.17 2.10 1.39–3.16
1998–2000 2.60 1.75–3.87 2.36 1.54–3.63
* Adjusted for all other cofactors in the table.
OR, odds ratio; CI, conﬁdence interval.
1120 F. Tyrer and otherswith a short test interval had a similarly increased risk
of AIDS, whether time was measured from the posi-
tive date (HR 1.46, 95% CI 1.06–2.03) or the mid-
point (HR 1.52, 95% CI 1.10–2.11).
DISCUSSION
We found a strong association between HIV test
interval and the presence of seroconversion illness in
persons enrolled on the UK Register, this was con-
sistent with our hypothesis that persons with symp-
toms compatible with seroconversion illness are more
likely to seek medical advice and/or request a repeat
test closer to the negative test than usual. We also
found that older individuals and those who sero-
converted more recently were more likely to report an
illness. This is likely to reﬂect a more heightened sus-
picion of HIV in older persons and those infected
more recently, when they present with illness sugges-
tive of HIV seroconversion. It may also be due to a
more complete ascertainment of illness in recent
years.
We also found that the length of the HIV test
interval was associated with progression to AIDS.
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Fig. 2. Kaplan–Meier graph of progression from seroconversion to AIDS by HIV test interval length, adjusted for age.
Table 3. The relationship between seroconversion illness, HIV test interval and progression to AIDS* (n=1820)
Variable
HIV test interval excluded from model HIV test interval included in model
HR 95% CI P value HR 95% CI P value
HIV test interval
>2 months 1.00 0.01
f2 months 1.49 1.11–2.00
No seroconversion illness 1.00 0.82 1.00 0.98
Seroconversion illness 1.09 0.82–1.45 0.98 0.73–1.31
Unknown seroconversion
illness status
1.01 0.80–1.27 1.01 0.80–1.28
* Adjusted for sex, age group, exposure category and calendar year at risk.
HR, hazards ratio; CI, conﬁdence interval.
Seroconversion illness and time to AIDS 1121It seems likely that this association reﬂects the
previously documented relationship between sero-
conversion illness and disease progression [2, 4, 5] and
that using a HIV test interval of f2 months best
captures this relationship. We did not ﬁnd an eﬀect of
seroconversion illness in our model, probably because
of incomplete information on seroconversion illness
in our cohort. As many as 41% of persons who sero-
converted prior to 1994, before the study was estab-
lished, had no information documented on illness.
Further, even when data are collected prospectively,
the report of symptoms is subject to recall bias for
individuals at the time of a positive test. Symptoms
reported were also general (e.g. ‘ ’ﬂu-like’ symptoms
and rash) and non-speciﬁc, although they varied
substantially between individuals but changed little
over time. Furthermore, it may not simply be the
presence or absence of illness, but its symptoms
and duration, which inﬂuence disease progression.
Pedersen et al. [4] reported that persons with an acute
illness lasting 14 days or longer, progressed to AIDS
more rapidly than those who were free of symptoms
or had a mild illness. It is not possible to consider a
link between severity of symptoms at seroconversion
and progression to AIDS [4, 12] in terms of using
the test interval as a proxy, because numbers with
severe illness are too small (Table 1). The inability to
account for speciﬁc symptoms, a level of detail that
is not readily available in most centres, may have
masked the eﬀect of illness on disease progression.
In adjusting for late entry, we minimize bias and
confounding from persons with short test intervals
presenting earlier in infection. Clearly however, indi-
viduals with a short test interval are unlikely to have
all presented due to the manifestations of sympto-
matic seroconversion. This population may also in-
clude people who are frequently tested because they
perceive themselves at risk of HIV infection. If these
individuals progress more rapidly to AIDS, for
example due to co-infection with other sexually
transmitted infections, the estimated eﬀect of a HIV
test interval of f2 months could be an over-estimate
of the eﬀect of interest, namely the eﬀect of sero-
conversion illness.
Furthermore, because individuals may be more
likely to seek testing after a high risk event, sero-
conversion may have actually occurred closer to the
date of the positive antibody test rather than the
midpoint between negative and positive test dates.
This may lead to an over-estimation of the time to
AIDS for persons with a longer HIV test interval, and
thus the association between test interval length and
time to AIDS found here may be an artefact. This is
unlikely, however, as results from the sensitivity
analysis measuring time from the midpoint between
tests were comparable to those measuring time from
the ﬁrst positive test date.
Conversely, patients with symptoms of acute pri-
mary infection may not have presented at a clinic
immediately, for example, if symptoms were mild
or if seroconversion illness was not initially thought
to be HIV-related. An increased risk of progression
to AIDS in this population would imply that the
estimated eﬀect of a short test interval could under-
estimate the true eﬀect of seroconversion illness.
Prospective studies have suggested that the relation-
ship between seroconversion illness and faster disease
progression may be due to higher or more variable
HIV RNA levels [13, 14] or because the seroconver-
sion illness itself is AIDS-deﬁning [15]. We have not
considered such explanatory pathways here.
Our ﬁndings highlight the diﬃculties in collecting
information on seroconversion illness both retro-
spectively and prospectively. They also demonstrate
that in the absence of well-recorded or complete
information on seroconversion illness, the HIV test
interval is an important factor for analyses of disease
progression.
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